(this["webpackJsonpumms-app"]=this["webpackJsonpumms-app"]||[]).push([[0],{56:function(e,n,o){},57:function(e,n,o){},66:function(e){e.exports=JSON.parse('{"drugs":[{"id":"1","name":"Yescarta\xae (Axicabtagene Ciloleucel)","packageInsertURL":"https://www.fda.gov/media/108377/download","gradeTypes":[{"name":"CRS Toxicity","grades":[{"name":"Grade 1","description":"Symptoms require symptomatic treatment only (i.e. fever, nausea, fatigue, headache, myalgia, malaise)","response":"Anti IL-6 and corticosteroids:\\n If in Grade 1 for <72h \u2013 none\\n\\n No improvement after 72h - Tociluzumab8mg/kg (not to exceed 800 mg) over 1 hr\\n Repeat every 4-6 hours as needed\\n+\\n Dexamethasone 10 mg x 1  \\n\\n Consider levetiracetam for seizure prophylaxis.\\n& No improvement after 24h - Tociluzumab8mg/kg (not to exceed 800 mg) over 1 hr. \\n\\n If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. \\n\\n If improving, discontinue tocilizumab.\\n& No improvement after 72h - Tociluzumab8mg/kg (not to exceed 800 mg) over 1 hr\\n\\n If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. \\n If improving, discontinue tocilizumab.\\n+\\n Dexamethasone 10 mg x 1\\n","followup":null},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention.\\nOxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":"Anti- IL-6 and corticosteroids: Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n+\\n Dexamethasone 10 mg intravenously once daily. If improving, manage as Grade 1  and continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. If not improving, manage as appropriate grade 3.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Should be monitored with continuous cardiac telemetry and pulse oximetry","followup":null},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention.\\nOxygen requirement greater than 40% FiO2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Anti IL-6 and corticosteroids: Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n+\\n Dexamethasone 10 mg intravenously three times a day. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. If not improving, manage as Grade 4.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Should be monitored with continuous cardiac telemetry and pulse oximetry. For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function. For severe or lifethreatening CRS, consider intensive-care supportive therapy\\n ","followup":null},{"name":"Grade 4","description":"Life threatening symptoms.\\nRequirements for ventilator support, CVVHD, or Grace 4 organ toxicity (excluding Grade 4 transaminitis)","response":"Anti IL-6 and Corticosteroids: Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n+\\n Methylprednisolone 1000 mg intravenously once per day for 3 days. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, consider methylprednisolone 1000 mg 2-3 times a day or alternate therapy.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Should be monitored with continuous cardiac telemetry and pulse oximetry. For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function. For severe or lifethreatening CRS, consider intensive-care supportive therapy\\n ","followup":null}]},{"name":"NeuroToxicity","grades":[{"name":"Grade 1","description":"Somnolence - mild drowsiness or sleepiness\\nConfusion - mild disorientation \\nEncephalopathy - mild limiting of ADLs \\nDysphasia - not impairing ability to communicate","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer tocilizumab per  Grade 1 CRS. In addition, administer one dose of dexamethasone 10 mg intravenously. If not improving after 2 days, repeat dexamethasone 10 mg intravenously.\\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "},{"name":"No","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer one dose of dexamethasone 10 mg intravenously.\\n If not improving after 2 days, repeat \\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities (Table 2). Rule out other causes of neurologic symptoms.\\n "}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n\\n Administer dexamethasone 10 mg intravenously four times a day. If improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. If not improving, manage as appropriate grade below.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "},{"name":"No","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer dexamethasone 10 mg intravenously four times a day. If improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. If not improving, manage as appropriate grade below.\\n\\n Consider levetiracetam for seizure prophylaxis.\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "}]}},{"name":"Grade 3","description":"Somnolence - obtundation or stupor \\nConfusion - severe disorientation \\nEncephalopathy - limiting self-care ADLs \\nDysphasia - severe receptive or expressive characteristics, impairing ab ability to read, write or communicate intelligibly ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n\\n Administer methylprednisolone 1000 mg intravenously once daily. If improving, manage as appropriate grade 2 and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, manage as Grade 4. \\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "},{"name":"No","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer methylprednisolone 1000 mg intravenously once daily. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, manage as Grade 4.\\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "}]}},{"name":"Grade 4","description":"Life threatening consequences \\nUrgent intervention indicated\\nRequirement for mechanical ventilation \\nConsider cerebral edema","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer tocilizumab  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24- hour period; maximum total of 4 doses. If improving, discontinue tocilizumab.\\n\\n Administer methylprednisolone 1000 mg intravenously twice per day. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, consider 1000 mg of methylprednisolone intravenously 3 times a day or alternate therapy\\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "},{"name":"No","response":"Anti- IL 6, Seizure Prophylaxis, and Corticosteroids: \\n\\n Administer methylprednisolone 1000 mg intravenously twice per day. If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate. If not improving, consider 1000 mg of methylprednisolone intravenously 3 times a day or alternate therapy.\\n\\n Consider levetiracetam for seizure prophylaxis\\n\\n Monitor patients for signs and symptoms of neurologic toxicities. Rule out other causes of neurologic symptoms.\\n "}]}}]}]},{"id":"2","name":"Breyanzi\xae (lisocabtagene maraleucel) ","packageInsertURL":"https://www.fda.gov/media/145711/download","gradeTypes":[{"name":"CRS Toxicity","grades":[{"name":"Grade 1","description":"Symptoms require symptomatic treatment only (i.e. fever, nausea, fatigue, headache, myalgia, malaise)","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"Anti IL-6 and corticosteroids:\\n\\n Consider Tociluzumab 8mg/kg over 1 hr (not to exceed 800 mg)\\n+\\n Consider Dexamethasone 10 mg x 1  every 24 hours (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper) \\n\\n Evaluate and treat for other causes of fever etc...\\n\\n Continue to monitor and treat symptomatically\\n\\n If concurrent Neurotoxicty: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. \\n"},{"name":"No (> 72 hours after infusion)","response":"Anti IL-6 and corticosteroids:\\n\\n None \\n\\n Evaluate and treat for other causes of fever etc...\\n\\n Continue to monitor and treat symptomatically.\\n"}]}},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention.\\n\\nOxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"Anti- IL-6 and corticosteroids:\\n\\n Tociluzumab8mg/kg over 1 hr (not to exceed 800 mg). Repeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n+\\n Dexamethasone 10 mg x IV every 12-24 hours (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper)\\n\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension.\\n\\n Continue to monitor and treat symptomatically\\n\\n If concurrent Neurotoxicty: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity.& If no improvement within 24 hours or rapid progression. Anti- IL-6 and corticosteroids: Repeat tociluzumab.\\n+\\n Escalate dose and frequency of dexamethasone (10- 20mg IV every 6-12 hours).\\n\\n If no improvement  or continued rapid progression, maximise dethamthasone, switch to methylprednisolone 2mg/kg  if needed  (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper.\\n\\n After 2 doses of Tocilizumab , consider alternative immunosuppressants. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n"},{"name":"No (> 72 hours after infusion)","response":"Anti- IL-6 and corticosteroids:\\n\\nTociluzumab8mg/kg over 1 hr (not to exceed 800 mg). Repeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n+\\n Consaider Dexamethasone 10 mg x IV every 12-24 hours (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper)\\n\\n Evaluate and treat for other causes of fever, hypoxia, and hypotension.\\n\\n Should be monitored with continuous cardiac telemetry and pulse oximetry. If concurrent Neurotoxicty: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity.& If no improvement within 24 hours or rapid progression. Anti- IL-6 and corticosteroids: Repeat tociluzumab. \\n+\\n Escalate dose and frequency of dexamethasone (10- 20mg IV every 6-12 hours).\\n\\n If no improvement  or continued rapid progression, maximise dethamthasone, switch to methylprednisolone 2mg/kg  if needed  (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper\\n\\n After 2 doses of Tocilizumab , consider alternative immunosuppressants. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n"}]}},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention.\\n\\nOxygen requirement greater than 40% FiO2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Anti- IL-6 and corticosteroids:\\n\\nTociluzumab8mg/kg over 1 hr (not to exceed 800 mg). Repeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n+\\n Dexamethasone 10 mg x IV every 12 hours (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper)\\n\\n Evaluate and treat for other causes of fever, hypoxia, and hypotension.\\n\\n For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function and intensive-care supportive therapy.\\n\\n If concurrent Neurotoxicty: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity.& If no improvement within 24 hours or rapid progression Anti- IL-6 and corticosteroids: \\n\\n Repeat tociluzumab. \\n+\\n Escalate dose and frequency of dexamethasone (10- 20mg IV every 6-12 hours).\\n\\n If no improvement  or continued rapid progression, maximise dethamthasone, switch to methylprednisolone 2mg/kg  if needed  (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper)\\n\\n After 2 doses of Tocilizumab , consider alternative immunosuppressants. . Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n","followup":null},{"name":"Grade 4","description":"Life threatening symptoms. including requirements for ventilator support, CVVHD, or Grace 4 organ toxicity (excluding Grade 4 transaminitis)","response":"Anti- IL-6 and corticosteroids:\\n\\nTocilizumab 8mg/kg over 1 hr (not to exceed 800 mg). Repeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n+\\n Dexamethasone 20 mg x IV every 6 hours (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper)\\n\\n Evaluate and treat for other causes of fever, hypoxia, and hypotension.\\n\\n For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function and intensive-care supportive therapy. &If no improvement within 24 hours or rapid progression Anti- IL-6 and corticosteroids: escalate tocilizumab and steroids use.\\n\\n If no improvement  or continued rapid progression, maximise dethamthasone, switch to methylprednisolone 2mg/kg  if needed  (for a minimum of 3 doses or until complete resolution of symptoms, and consider a steroid taper) After 2 doses of Tocilizumab , consider alternative immunosuppressants. . Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n","followup":null}]},{"name":"NeuroToxicity","grades":[{"name":"Grade 1","description":"Somnolence - mild drowsiness or sleepiness\\n\\nConfusion - mild disorientation \\n\\nEncephalopathy - mild limiting of ADLs \\n\\nDysphasia - not impairing ability to communicate","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"If Grade 1 < 72 hours after the infusion Consider Dexamethasone 10 mg   every 12 to 24 hours for  2-3 days\\n\\n Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n Start levetiraetam  or other nonsedating medications for antiseizure prophylaxis\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.\\n"},{"name":"No (> 72 hours after infusion)","response":"> 72 hours after the infusion Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n Start levetiraetam  or other nonsedating medications for seizure prophylaxis.\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS. \\n"}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n","response":"Start levetiraetam  or other nonsedating medications for seizure prophylaxis\\n\\n Start Dexamethasone 10 mg  every 12 hours for  2-3 days or longer with persistant symptoms. Consider taper for total steroid exposure of greater than 3 days. Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n If no improvement after 24 hrs or worsening neurologic toxicity increase the dose and/or frequency of dexamethasone up to a maximum of 20mg IV every 6 hours.\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.& If no improvement after 24 hrs or worsening neurologic toxicity increase the dose and/or frequency of dexamethasone up to a maximum of 20mg IV every 6 hours.\\n\\n If no improvement after  another 24 hrs, rapidly progressing symptoms, or life-threatening complications arrise,  give methylprednisolone 2 mg/kg loading dose, followed by 2 mg/kg divided 4 times a day; taper witin 7 days.\\n","followup":null},{"name":"Grade 3","description":"Somnolence - obtundation or stupor \\n\\nConfusion - severe disorientation \\n\\nEncephalopathy - limiting self-care ADLs \\n\\nDysphasia - severe receptive or expressive characteristics, impairing ab ability to read, write or communicate intelligibly ","response":"Start levetiraetam  or other nonsedating medications for seizure prophylaxis\\n\\n Start dexamethasone 10-20 mg IV every 8-12 hours. Corticosteroids are not recommended for isolated grade 3 headaches.\\n\\n Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n If cerebral edema is suspected consider hyperventilation and hyperosmolar therapy. Give methylprednislone 1-2 g (every 24 hours if needed, taper as indicated) and cyclophosphamide 1.5 g/m2\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.&If no improvement after 24 hrs or worsening neurologic toxicity escalate to methylprenisolone 2 mg/kg loading dose, followed by 2 mg/kg divided 4 times a day; taper witin 7 days.\\n","followup":null},{"name":"Grade 4","description":"Life threatening consequences \\n\\nUrgent intervention indicated\\n\\nRequirement for mechanical ventilation \\n\\nConsider cerebral edema","response":"Start levetiraetam  or other nonsedating medications for antiseizure prophylaxis\\n\\n Start dexamethasone 20 mg IV every 6 hours. \\n\\n If cerebral edema is suspected consider hyperventilation and hyperosmolar therapy. Give methylprednislone 1-2 g (every 24 hours if needed, taper as indicated) and cyclophosphamide 1.5 g/m2\\n\\n Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.&If no improvement after 24 hrs or worsening neurologic toxicity escalate to methylprenisolone 2 mg/kg loading dose, followed by 2 mg/kg divided 4 times a day; taper witin 7 days.\\n","followup":null}]}]},{"id":"3","name":"Abecma\xae (Idecabtagene vicleucel)","packageInsertURL":"https://www.fda.gov/media/147055/download","gradeTypes":[{"name":"CRS Toxicity","grades":[{"name":"Grade 1","description":"Symptoms require symptomatic treatment only (i.e. fever, nausea, fatigue, headache, myalgia, malaise)","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"< 72 hours after the infusion\\n\\n Anti IL-6 and corticosteroids: Consider Tocilizumab8mg/kg (not to exceed 800 mg) over 1 hr\\n+\\n Consider Dexamethasone 10 mg x 1  every 24 hours (if steroids are started continue for a minimum of 3 doses taper 7 maximum 7 days)\\n\\n Consider antiseizure prophylaxis with levetiracetam in patients who experience CRS.\\n\\n Evaluate and treat for other causes of fever, etc...\\n\\n Continue to monitor and treat symptomatically. \\n"},{"name":"No (> 72 hours after infusion)","response":"> 72 hours after the infusion\\n\\n Anti IL-6 and corticosteroids:\\n\\n Consider Dexamethasone 10 mg IV every 24 hours.(if steroids are started continue for a minimum of 3 doses taper 7 maximum 7 days)\\n\\n Evaluate and treat for other causes of fever, etc...\\n\\n Consider antiseizure prophylaxis with levetiracetam in patients who experience CRS.\\n\\n Continue to monitor and treat symptomatically\\n"}]}},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention.\\n\\nOxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":"Anti- IL-6 and corticosteroids: \\n\\nTocilizumab8mg/kg (not to exceed 800 mg) over 1 hr Repeat every 8 hours as needed if not responsive to IV fluids or increasing supplimental oxygen. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n+\\n Consider Dexamethasone 10 mg x IV every 12-24 hours . (if steroids are started continue for a minimum of 3 doses taper 7 maximum 7 days)\\n\\n Consider antiseizure prophylaxis with levetiracetam in patients who experience CRS.\\n\\n Evaluate and treat for other causes of fever, hypoxia, and hypotension.\\n\\n Should be monitored with continuous cardiac telemetry and pulse oximetry&If no improvement within 24 hours or rapid progression, repeat tocilizumab and escalate dose and frequency of dexamethasone (20mg IV every 6-12 hours).\\n\\n If no improvement within 24 hours or continued rapid progression, switch to methylprednisolone 2mg/kg followed by 2 mg/kg divided 4 times per day.\\n\\n After 2 doses of tocilizumab, consider anti-cytokine agens. \\n\\n Do not exceed 3 doses of tocilizumab in 24 hours, or 4 doses in total.\\n","followup":null},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention.\\n\\nOxygen requirement greater than 40% FiO2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Anti- IL-6 and corticosteroids:\\n\\n Tocilizumab8mg/kg (not to exceed 800 mg) over 1 hr Repeat every 8 hours as needed if not responsive to IV fluids or increasing supplimental oxygen. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses.\\n+\\n Dexamethasone 10 mg x IV every 12 hours  (for a minimum of 3 doses taper 7 maximum 7 days)\\n\\n Consider antiseizure prophylaxis with levetiracetam in patients who experience CRS.\\n\\n Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n\\n consider intensive care unit level monitoring and supportive therapy\\n\\n &If no improvement within 24 hours or rapid progression, repeat tociluzumab and escalate dose and frequency of dexamethasone (20mg IV every 6-12 hours).(for a minimum of 3 doses taper 7 maximum 7 days)\\n\\n If no improvement within 24 hours or continued rapid progression, switch to methylprednisolone 2mg/kg followed by 2 mg/kg divided 4 times per day.(for a minimum of 3 doses taper 7 maximum 7 days)\\n\\n After 2 doses of tocilizumab, consider alternative anti-cytokine agents. \\n\\n Do not exceed 3 doses of tocilizumab in 24 hours, or 4 doses in total.\\n","followup":null},{"name":"Grade 4","description":"Life threatening symptoms.\\n\\nRequirements for ventilator support, CVVHD, or Grace 4 organ toxicity (excluding Grade 4 transaminitis)","response":"Anti- IL-6 and corticosteroids:\\n\\nTocilizumab8mg/kg (not to exceed 800 mg) over 1 hr Repeat every 8 hours as needed if not responsive to IV fluids or increasing supplimental oxygen. Limit to a max of 3 doses in 24 hour period; maximum total of 4 doses. After 2 doses of tocilizumab, consider alternative anti-cytokine agents.\\n+\\n Dexamethasone 10 mg x IV every 6 hours  (for a minimum of 3 doses taper 7 maximum 7 days)\\n\\n Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n\\n consider intensive care unit level monitoring and supportive therapy\\n\\n &If no improvement within 24 hours, consider methylprednisolone (1-2 g, repeat every 24 hours if needed; taper as clinically indicated) or other anti-T cell therapies.(for a minimum of 3 doses taper 7 maximum 7 days) and other anti-T cell therapies\\n","followup":null}]},{"name":"NeuroToxicity","grades":[{"name":"Grade 1","description":"Somnolence - mild drowsiness or sleepiness\\n\\nConfusion - mild disorientation \\n\\nEncephalopathy - mild limiting of ADLs \\n\\nDysphasia - not impairing ability to communicate","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"If Grade 1 < 72 hours after the infusion\\n\\n Consider Dexamethasone 10 mg every 12 to 24 hours for  2-3 days\\n\\n Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n Start levetiraetam  or other nonsedating medications for antiseizure prophylaxis\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.\\n"},{"name":"No (> 72 hours after infusion)","response":"If Grade 1 > 72 hours after the infusion\\n\\n Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n Start levetiraetam  or other nonsedating medications for seizure prophylaxis.\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.\\n"}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n","response":"Start levetiraetam  or other nonsedating medications for antiseizure prophylaxis.\\n\\n Start Dexamethasone 10 mg  every 12 hours for  2-3 days or longer with persistant symptoms. Consider taper if > 3 days. Steroids not indiated for isolated Grade 2 headaches. \\n\\n Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.&If no improvement after 24 hrs or worsening neurologic toxicity increase the dose and/or frequency of dexamethasone up to a maximum of 20mg IV every 6 hours.\\n","followup":null},{"name":"Grade 3","description":"Somnolence - obtundation or stupor \\n\\nConfusion - severe disorientation \\n\\nEncephalopathy - limiting self-care ADLs \\n\\nDysphasia - severe receptive or expressive characteristics, impairing ab ability to read, write or communicate intelligibly ","response":"Start dexamethasone 10-20 mg IV every 6-12 hours. Corticosteroids are not recommended for isolated grade 3 headaches. If no improvement after 24 hours or worsening neurotoxicity methylprednisolone 1-2 g, every 24 houts as needed.\\n\\n Rule out other causes of neurological signs and symptoms.  Consider intensive care unit level monitoring and supportive therapy\\n\\n Start levetiraetam  or other nonsedating medications for antiseizure prophylaxis\\n\\n If cerebral edema is suspected consider hyperventilation and hyperosmolar therapy. Give methylprednislone 1-2 g very 24 hours if needed, taper as indicated and cyclophosphamide 1/5 g/m2\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.\\n","followup":null},{"name":"Grade 4","description":"Life threatening consequences \\n\\nUrgent intervention indicated\\n\\nRequirement for mechanical ventilation \\n\\nConsider cerebral edema","response":"Start dexamethasone 20 mg IV every 6 hours. \\n\\n If no improvement after 24 hours or worsening neurotoxicity methylprednisolone 1-2 g, every 24 houts as needed.\\n\\n Rule out other causes of neurological signs and symptoms. Provide supportive care.\\n\\n Start levetiraetam  or other nonsedating medications for antiseizure prophylaxis\\n\\n If cerebral edema is suspected consider hyperventilation and hyperosmolar therapy. Give methylprednislone 1-2 g very 24 hours if needed, taper as indicated and cyclophosphamide 1/5 g/m2\\n\\n If concurrent CRS: steroids are to be dosed according to the more aggressive dosing for either CRS or Neurotoxicity. Tocilizumab is dosed according to CRS.\\n","followup":null}]}]}]}')},68:function(e,n,o){"use strict";o.r(n);var t,i,r,a,s,c,d,m=o(0),p=o.n(m),l=o(22),u=o.n(l),h=(o(56),o(11)),g=(o(57),o(79)),f=o(25),b=o.p+"static/media/logo.412a2035.jpg",y=o(80),x=o(73),v=o(74),j=o(82),O=o(4),w=o(5),I=o(70),C=o(71),S=o(72),z=w.b.img(t||(t=Object(O.a)(["\n    width: 90%;\n    height: 100%;\n    // margin-top: 5%;\n"]))),R=Object(w.b)(I.a)(i||(i=Object(O.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n"]))),k=Object(w.b)(I.a)(r||(r=Object(O.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n    align-items: center;\n    position:fixed;\n    left:0;\n    bottom:0;\n    right:0;\n"]))),A=Object(w.b)(C.a)(a||(a=Object(O.a)(["\n    font-size: 300%;\n"]))),L=Object(w.b)(j.a)(s||(s=Object(O.a)(["\n    // display: flex;\n    flex-direction: row;\n    // background-color: red;\n    align-items: center;\n    // border: 2px solid rgba(0,0,0,.125);\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n"]))),G=Object(w.b)(S.a)(c||(c=Object(O.a)(["\n    margin-right: 1%;\n"]))),T=Object(w.b)(I.a)(d||(d=Object(O.a)(["\n    justify-content: center;\n    margin-top: 9%;\n"]))),D=o(8),q=o(20),N=function(e,n){var o=null;if(n===[null])return null;var t,i=Object(q.a)(n);try{for(i.s();!(t=i.n()).done;){var r,a=t.value,s=Object(q.a)(e);try{for(s.s();!(r=s.n()).done;){var c=r.value;if(c.name===a){e=c,o=c;break}}}catch(d){s.e(d)}finally{s.f()}}}catch(d){i.e(d)}finally{i.f()}return o},V=function(e,n){e.push("".concat(window.location.pathname).concat(n,"/"))},F=o(1);var E,P,M,Y,B,H,U,J,K,W,_=function(){var e=Object(D.f)(),n=Object(m.useState)(!0),o=Object(f.a)(n,2),t=o[0],i=o[1],r=Object(m.useState)(!1),a=Object(f.a)(r,2),s=a[0],c=a[1],d=function(){return i(!1)};return Object(F.jsxs)(F.Fragment,{children:[Object(F.jsx)(R,{children:Object(F.jsx)(z,{src:b,alt:"logo"})}),"BETA VERSION",Object(F.jsxs)(y.a,{centered:!0,show:t,onHide:d,backdrop:"static",keyboard:!1,children:[Object(F.jsx)(y.a.Header,{children:Object(F.jsx)("h5",{children:"Are you a healthcare professional?"})}),Object(F.jsx)(y.a.Body,{children:Object(F.jsx)("h6",{children:"You are going to a website that contains clinical information and was created specifically for healthcare professionals."})}),Object(F.jsxs)(y.a.Footer,{children:[Object(F.jsx)(x.a,{variant:"secondary",onClick:function(){i(!1),c(!0)},children:"No"}),Object(F.jsx)(x.a,{variant:"primary",onClick:d,children:"Yes"})]})]}),Object(F.jsx)(y.a,{centered:!0,show:s,backdrop:"static",keyboard:!1,children:Object(F.jsx)(y.a.Body,{children:Object(F.jsx)("h5",{children:"This information is designed for healthcare professionals."})})}),Object(F.jsx)(T,{children:Object(F.jsxs)(v.a,{children:[Object(F.jsxs)(L,{children:[Object(F.jsx)(A,{}),Object(F.jsx)(j.a.Body,{children:Object(F.jsx)(j.a.Title,{children:"Toxicity Grading"})})]}),Object(F.jsxs)(L,{onClick:function(){return V(e,"toxicitymanagement")},children:[Object(F.jsx)(A,{}),Object(F.jsx)(j.a.Body,{children:Object(F.jsx)(j.a.Title,{children:"Toxicity Management"})})]})]})}),Object(F.jsxs)(k,{children:[Object(F.jsx)(G,{onClick:function(){return V(e,"aboutus")}}),Object(F.jsx)("span",{children:"About Us"})]})]})},Q=o(75),X=(w.b.img(E||(E=Object(O.a)(["\n  width: 90%;\n  height: 100%;\n  // margin-top: 5%;\n"]))),Object(w.b)(I.a)(P||(P=Object(O.a)(["\n  // padding-bottom: 4%;\n  // padding-top: 4%;\n  // box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n  //   rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  // justify-content: center;\n  background-color: rgb(26 23 24 / 100%);\n  color: rgb(255 255 255 / 100%);\n\n  position: sticky;\n  position: -webkit-sticky;\n  z-index: 10;\n  top: 0px;\n"])))),Z=Object(w.b)(Q.a)(M||(M=Object(O.a)(["\n  font-size: 175%;\n  margin: 3%;\n  position: absolute;\n"]))),$=w.b.div(Y||(Y=Object(O.a)(["\n  font-size: x-large;\n  margin: auto;\n  margin-top: 2%;\n  margin-bottom: 2%;\n"])));Object(w.b)(I.a)(B||(B=Object(O.a)(["\n  padding-bottom: 4%;\n  padding-top: 4%;\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  justify-content: center;\n  align-items: center;\n  position: fixed;\n  left: 0;\n  bottom: 0;\n  right: 0;\n"]))),Object(w.b)(C.a)(H||(H=Object(O.a)(["\n  font-size: 300%;\n"]))),Object(w.b)(j.a)(U||(U=Object(O.a)(["\n  // display: flex;\n  flex-direction: row;\n  // background-color: red;\n  align-items: center;\n  // border: 2px solid rgba(0,0,0,.125);\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n"]))),Object(w.b)(S.a)(J||(J=Object(O.a)(["\n  margin-right: 1%;\n  vertical-align: text-bottom;\n"]))),Object(w.b)(I.a)(K||(K=Object(O.a)(["\n  justify-content: center;\n  margin-top: 9%;\n"]))),Object(w.b)(j.a.Header)(W||(W=Object(O.a)(["\n  justify-content: space-between;\n  display: flex;\n  align-items: center;\n  background-color: unset;\n  border-bottom: unset;\n"])));var ee,ne=function(e){var n=e.data,o=n.split("\xae");n=o.length>=2?o[0]+"\xae":o[0];var t=Object(D.f)();return Object(F.jsx)(F.Fragment,{children:Object(F.jsxs)(X,{children:[Object(F.jsx)(Z,{onClick:function(){return t.goBack()}}),Object(F.jsx)($,{children:n})]})})};function oe(){var e=new Date(document.lastModified);return"".concat(e.getMonth()+1,"/").concat(e.getDate(),"/").concat(e.getFullYear())}var te,ie,re,ae,se,ce,de,me,pe=function(){return Object(F.jsxs)(F.Fragment,{children:[Object(F.jsx)(ne,{data:"About Us"}),Object(F.jsxs)("ul",{children:[Object(F.jsx)(le,{children:"This website/application is designed to make proper use of CAR-T cell therapies simpler to understand"}),Object(F.jsx)(le,{children:'All information on this website/application is based on publicly published FDA documents linked in the "Toxicity Management" page.'}),Object(F.jsx)(le,{children:" We are not responsible for any misuse of any the described drugs or any mistreatment done as a result of this application."}),Object(F.jsxs)(le,{children:["This code was last updated on ",oe(),"."]})]})]})},le=w.b.li(ee||(ee=Object(O.a)(["\n    width: 100%;\n    text-align: left;\n    position: relative;\n    padding: 2%;\n    margin-bottom: unset;\n"]))),ue=(w.b.img(te||(te=Object(O.a)(["\n  width: 90%;\n  height: 100%;\n  // margin-top: 5%;\n"]))),Object(w.b)(I.a)(ie||(ie=Object(O.a)(["\n  padding-bottom: 4%;\n  padding-top: 4%;\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  justify-content: center;\n"]))),Object(w.b)(I.a)(re||(re=Object(O.a)(["\n  padding-bottom: 4%;\n  padding-top: 4%;\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  justify-content: center;\n  align-items: center;\n  position: fixed;\n  left: 0;\n  bottom: 0;\n  right: 0;\n"]))),Object(w.b)(C.a)(ae||(ae=Object(O.a)(["\n  font-size: 300%;\n"]))),Object(w.b)(j.a)(se||(se=Object(O.a)(["\n  // display: flex;\n  flex-direction: row;\n  // background-color: red;\n  align-items: center;\n  // border: 2px solid rgba(0,0,0,.125);\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n"])))),he=Object(w.b)(S.a)(ce||(ce=Object(O.a)(["\n  margin-right: 1%;\n  vertical-align: text-bottom;\n"]))),ge=Object(w.b)(I.a)(de||(de=Object(O.a)(["\n  justify-content: center;\n  margin-top: 9%;\n"]))),fe=Object(w.b)(j.a.Header)(me||(me=Object(O.a)(["\n  justify-content: space-between;\n  display: flex;\n  align-items: center;\n  background-color: unset;\n  border-bottom: unset;\n"])));var be,ye,xe,ve,je,Oe,we,Ie,Ce=function(e){var n,o=Object(D.f)(),t=e.data.drugs,i=[],r=Object(q.a)(t);try{var a=function(){var e=n.value;i.push(Object(F.jsx)("div",{onClick:function(){return V(o,e.name)},children:Object(F.jsx)(ue,{children:Object(F.jsx)(j.a.Title,{children:Object(F.jsxs)(fe,{children:[e.name,Object(F.jsx)("a",{href:e.packageInsertURL,target:"_blank",rel:"noreferrer noopener",onClick:function(e){return e.stopPropagation()},children:Object(F.jsx)(he,{})})]})})})},"".concat(e.name," card")))};for(r.s();!(n=r.n()).done;)a()}catch(s){r.e(s)}finally{r.f()}return Object(F.jsxs)(F.Fragment,{children:[Object(F.jsx)(ne,Object(h.a)(Object(h.a)({},e),{},{data:"Toxicity Management"})),Object(F.jsx)(ge,{children:Object(F.jsx)(v.a,{children:i})})]})},Se=o(29),ze=(w.b.img(be||(be=Object(O.a)(["\n  width: 90%;\n  height: 100%;\n  // margin-top: 5%;\n"]))),Object(w.b)(I.a)(ye||(ye=Object(O.a)(["\n  padding-bottom: 4%;\n  padding-top: 4%;\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  justify-content: center;\n"]))),Object(w.b)(I.a)(xe||(xe=Object(O.a)(["\n  padding-bottom: 4%;\n  padding-top: 4%;\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  justify-content: center;\n  align-items: center;\n  position: fixed;\n  left: 0;\n  bottom: 0;\n  right: 0;\n"]))),Object(w.b)(C.a)(ve||(ve=Object(O.a)(["\n  font-size: 300%;\n"]))),Object(w.b)(j.a)(je||(je=Object(O.a)(["\n  // display: flex;\n  flex-direction: row;\n  // background-color: red;\n  align-items: center;\n  // border: 2px solid rgba(0,0,0,.125);\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n"])))),Re=(Object(w.b)(S.a)(Oe||(Oe=Object(O.a)(["\n  margin-right: 1%;\n  vertical-align: text-bottom;\n"]))),Object(w.b)(I.a)(we||(we=Object(O.a)(["\n  justify-content: center;\n  margin-top: 9%;\n"]))));Object(w.b)(j.a.Header)(Ie||(Ie=Object(O.a)(["\n  justify-content: space-between;\n  display: flex;\n  align-items: center;\n  background-color: unset;\n  border-bottom: unset;\n"])));var ke,Ae,Le,Ge,Te,De,qe,Ne,Ve,Fe,Ee,Pe,Me,Ye,Be=function(e){var n=e.data,o=Object(D.g)().drugtype,t=N(n.drugs,[o]).gradeTypes,i=Object(D.f)();return Object(F.jsxs)(F.Fragment,{children:[Object(F.jsx)(ne,Object(h.a)(Object(h.a)({},e),{},{data:o})),Object(F.jsx)(Re,{children:Object(F.jsxs)(v.a,{children:[Object(F.jsx)("div",{onClick:function(e){V(i,t[0].name)},children:Object(F.jsx)(ze,{children:Object(F.jsx)(j.a.Body,{children:Object(F.jsx)(j.a.Title,{children:t[0].name})})})}),Object(F.jsx)("div",{onClick:function(){return V(i,t[1].name)},children:Object(F.jsx)(ze,{children:Object(F.jsx)(j.a.Body,{children:Object(F.jsx)(j.a.Title,{children:t[1].name})})})})]})})]})},He=o(81),Ue=o(77),Je=o(78),Ke=o(76),We=(w.b.img(ke||(ke=Object(O.a)(["\n    width: 90%;\n    height: 100%;\n    // margin-top: 5%;\n"]))),Object(w.b)(I.a)(Ae||(Ae=Object(O.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n"]))),Object(w.b)(I.a)(Le||(Le=Object(O.a)(["\n    padding-bottom: 4%;\n    padding-top: 4%;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n    align-items: center;\n    position:fixed;\n    left:0;\n    bottom:0;\n    right:0;\n"]))),Object(w.b)(C.a)(Ge||(Ge=Object(O.a)(["\n    font-size: 300%;\n"]))),Object(w.b)(j.a)(Te||(Te=Object(O.a)(["\n    // display: flex;\n    // flex-direction: row;\n    // background-color: red;\n    // align-items: center;\n    // border: 2px solid rgba(0,0,0,.125);\n    // box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    border: unset;\n"])))),_e=Object(w.b)(Ke.a)(De||(De=Object(O.a)(["\n    margin-right: 1%;\n    transform: rotate(0deg);\n    transition: transform .2s ease-out;\n\n    ",";\n"])),(function(e){return e.activated&&Object(w.a)(qe||(qe=Object(O.a)(["\n        transform: rotate(180deg);\n  "])))})),Qe=Object(w.b)(I.a)(Ne||(Ne=Object(O.a)(["\n    justify-content: center;\n    // margin-top: 9%;\n"]))),Xe=Object(w.b)(He.a)(Ve||(Ve=Object(O.a)(["\n    width: 100%;\n    display: flex;\n    flex-direction: column;\n    justify-content: space-around;\n"]))),Ze=Object(w.b)(j.a.Header)(Fe||(Fe=Object(O.a)(["\n    justify-content: space-between;\n    display: flex;\n    align-items: center;\n    background-color: unset;\n    border-bottom: unset;\n"]))),$e=Object(w.b)(Ue.a)(Ee||(Ee=Object(O.a)(["\n    width: 100%;\n    text-align: left;\n    position: relative;\n    padding: 2%;\n    margin-bottom: unset;\n"]))),en=Object(w.b)(Ue.a)(Pe||(Pe=Object(O.a)(["\n    width: 100%;\n    text-align: left;\n    padding: 2%;\n    margin-bottom: unset;\n    position: sticky;\n    position: -webkit-sticky;\n    border-radius: unset;\n    z-index: 10;\n\n    ",";\n"])),(function(e){return Object(w.a)(Me||(Me=Object(O.a)(["\n        top: ","px;\n    "])),e.top)})),nn=Object(w.b)(Je.a)(Ye||(Ye=Object(O.a)(["\n    width: 100%;\n"])));var on=function(e){Object(D.f)();var n,o=e.data,t=Object(D.g)(),i=t.drugtype,r=t.managementtype,a=N(N(o.drugs,[i]).gradeTypes,[r]).grades,s=Object(m.useState)(""),c=Object(f.a)(s,2),d=c[0],p=c[1],l=Object(m.useState)(""),u=Object(f.a)(l,2),g=u[0],b=u[1],y=Object(m.useState)(""),v=Object(f.a)(y,2),O=v[0],w=v[1],I=[],C=Object(q.a)(a);try{var S=function(){var e=n.value;I.push(Object(F.jsx)(We,{children:Object(F.jsxs)(x.a,{variant:"outline-primary",active:e.name===g,onClick:function(n){b(e.name),w("")},children:[Object(F.jsxs)(Ze,{children:[e.name,Object(F.jsx)(He.a.Toggle,{as:"div",variant:"",eventKey:e.name,onClick:function(n){return o=e.name,void p(d===o?"":o);var o},children:Object(F.jsx)(_e,{activated:e.name===d})})]}),Object(F.jsx)(He.a.Collapse,{eventKey:e.name,children:Object(F.jsx)(j.a.Body,{children:e.description})})]},"".concat(e.name," card"))}))};for(C.s();!(n=C.n()).done;)S()}catch(E){C.e(E)}finally{C.f()}var z=N(a,[g]),R=[];if(z&&z.followup){var k,A=Object(q.a)(z.followup.options);try{var L=function(){var e=k.value;R.push(Object(F.jsx)(x.a,{variant:"outline-primary",active:e.name===O,onClick:function(){return w(e.name)},children:e.name},"".concat(e.name," option")))};for(A.s();!(k=A.n()).done;)L()}catch(E){A.e(E)}finally{A.f()}}var G,T=function(e){var n,o=e.split(/&|\n\n/),t=[],i=Object(q.a)(o);try{for(i.s();!(n=i.n()).done;){var r=n.value;t.push(r.split("\n"))}}catch(E){i.e(E)}finally{i.f()}return t.map((function(e,n){return 0==e?null:Object(F.jsx)("li",{children:e},"list item ".concat(Math.random()))}))},V=function(e){var n=Object(m.useRef)(),o=e.hasFollowup;return Object(m.useEffect)((function(){})),Object(F.jsxs)($e,{variant:"success",ref:n,children:[Object(F.jsx)("h4",{children:"Recommended Treatment:"}),o?Object(F.jsx)("ul",{children:T(N(z.followup.options,[O]).response)}):Object(F.jsx)("ul",{children:T(z.response)})]},"response")};return Object(F.jsxs)(F.Fragment,{children:[Object(F.jsx)(ne,Object(h.a)(Object(h.a)({},e),{},{data:r})),Object(F.jsxs)(Qe,{children:[Object(F.jsxs)(en,{variant:"dark",top:"51",children:["Select Toxicity Grade:\xa0",Object(F.jsx)("strong",{children:g})]},"grade-prompt"),Object(F.jsx)(Xe,{children:I}),g&&(z.followup?Object(F.jsxs)(F.Fragment,{children:[Object(F.jsxs)(en,{variant:"dark",top:"91",children:[z.followup.name,"\xa0",Object(F.jsx)("strong",{children:(G=O,G.split("(")[0])})]},"followup-prompt"),Object(F.jsx)(nn,{children:R}),O&&Object(F.jsx)(V,Object(h.a)(Object(h.a)({},e),{},{hasFollowup:!0}))]}):Object(F.jsx)(V,Object(h.a)(Object(h.a)({},e),{},{hasFollowup:!1})))]})]})},tn=o(66);var rn=function(){return Object(F.jsx)(Se.a,{children:Object(F.jsx)(g.a,{fluid:!0,className:"App",children:Object(F.jsxs)(D.c,{children:[Object(F.jsx)(D.a,{path:"/toxicitymanagement/:drugtype/:managementtype/",render:function(e){return Object(F.jsx)(on,Object(h.a)(Object(h.a)({},e),{},{data:tn}))}}),Object(F.jsx)(D.a,{path:"/toxicitymanagement/:drugtype/",render:function(e){return Object(F.jsx)(Be,Object(h.a)(Object(h.a)({},e),{},{data:tn}))}}),Object(F.jsx)(D.a,{exact:!0,path:"/toxicitymanagement/",render:function(e){return Object(F.jsx)(Ce,Object(h.a)(Object(h.a)({},e),{},{data:tn}))}}),Object(F.jsx)(D.a,{exact:!0,path:"/aboutus",component:pe}),Object(F.jsx)(D.a,{exact:!0,path:"/",component:_})]})})})},an=function(e){e&&e instanceof Function&&o.e(3).then(o.bind(null,83)).then((function(n){var o=n.getCLS,t=n.getFID,i=n.getFCP,r=n.getLCP,a=n.getTTFB;o(e),t(e),i(e),r(e),a(e)}))};o(67);u.a.render(Object(F.jsx)(p.a.StrictMode,{children:Object(F.jsx)(rn,{})}),document.getElementById("root")),an()}},[[68,1,2]]]);
//# sourceMappingURL=main.b50a5f99.chunk.js.map